Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

We are delighted to welcome Stephen to TScan at this stage of growth for the Company,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “His robust commercial leadership experience includes over ...

Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several ...